Changes in von Willebrand factor-cleaving protease (ADAMTS13) activity after infusion of desmopressin

Blood

Volumn 101, Issue 3, 2003, Pages 946-948

  Reiter, Rosemarie A ^a   Knöbl, Paul ^a,b   Varadi, Katalin ^a   Turecek, Peter L ^a  

^a Baxter Bio Science   (Austria)

^b UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; COLLAGEN; DESMOPRESSIN; POLYMER; PROTEINASE; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ADULT; ARTICLE; CASE REPORT; DRUG EFFECT; DRUG INFUSION; ENZYME ACTIVITY; ENZYME REGULATION; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; VON WILLEBRAND DISEASE;

EID: 0037305592     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-03-0814     Document Type: Article

References (17)

1. Wagner DD, Fay PJ, Sporn LA, Sinha S, Lawrence SO, Marder VJ. Divergent fates of von Willebrand factor and its propolypeptide (von Willebrand antigen II) after secretion from endothelial cells. Proc Natl Acad Sci U S A. 1987;84:1955-1959.
2. Sadler JE. Biochemistry and genetics of von Willebrand factor. Annu Rev Biochem. 1998;67:395-424.
3. Sadler JE, Mannucci PM, Berntorp E, et al. Impact, diagnosis and treatment of von Willebrand disease. Thromb Haemost. 2000;84:160-174.
4. Furlan M. Von Willebrand factor: molecular size and functional activity. Ann Hematol. 1996;72:341-348.
5. Zheng X, Chung D, Takayama TK, Majerus EM, Sadler JE, Fujikawa K. Structure of von Willebrand factor cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J Biol Chem. 2001;276:41059-41063.
6. Moake JL, Turner NA, Stathopoulos NA, Nolasco LH, Hellums JD. Involvement of large plasma von Willebrand factor (vWF) multimers and unusually large vWF forms derived from endothelial cells in shear stress-induced platelet aggregation. J Clin Invest. 1986;78:1456-1461.
7. Oleksowicz L, Bhagwati N, DeLeon-Fernandez M. Deficient activity of von Willebrand's factorcleaving protease in patients with disseminated mallgnancies. Canc Res. 1999;59:2244-2250.
8. Mannucci PM, Canciani MT, Forza I, Lussana F, Lattuada A, Rossi E. Changes in health and disease of the metalloprotease that cleaves von Willebrand factor. Blood. 2001;98:2730-2735.
9. Mannucci PM. Desmopressin (DDAVP) in the treatment of bleeding disorders: the first 20 years. Blood. 1997;90:2515-2521.
10. Turecek PL, Pichler L, Auer W, et al. Evidence for extracellular processing of pro-von Willebrand factor after infusion in animals with and without severe von Willebrand disease. Blood. 1999;94:1637-1647.
11. Siekmann J, Turecek PL, Schwarz HP. The determination of von Willebrand factor activity by collagen binding assay. Haemophilia. 1998;4(suppl 3):15-24.
12. Varadi K, Turecek PL, Mitterer A, Dorner F, Schwarz HP. Thrombin-mediated in vitro processing of pro-von Willebrand factor. Thromb Haemost. 2001;86:1449-1458.
13. Gerritsen A, Turecek PL, Schwarz HP, Lämmle B, Furlan M. Assay of von Willebrand factor (VWF)cleaving protease based on decreased collagen binding affinity of degraded VWF. Thromb Haemost. 1999;82:1386-1389.
14. Turecek PL, Gritsch H, Pichler L, et al. In vivo characterization of recombinant von Willebrand factor in dogs with von Willebrand disease. Blood. 1997;90:3555-3567.
15. Knöbl P, Laczika K, Staudinger T, et al. Kinetics of inhibitors of von Willebrand factor cleaving metalloprotease in three patients with severe thrombotic thrombocytopenic purpura. Annals Hematol. 2002;81(suppl 1):A42.
16. Borchiellini A, Fijnvandraat K, ten Cate JW, et al. Quantitative analysis of von Willebrand factor propeptide release in vivo: effect of experimental endotoxemia and administration of 1-deamino-8D-arginin vasopressin in humans. Blood. 1996;88:2951-2958.
17. Vischer UM, Ingerslev J, Wollheim CB, et al. Acute von Willebrand factor secretion from endothelium in vivo: assessment through propeptide vVWF: Agll levels. Thromb Haemost. 1997;77:387-393.